Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Newman

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Journal of the American College of Cardiology|April 26, 2011
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trialGregg W Stone, Ali Rizvi, Krishnankutty Sudhir, et al.
Lancet (London, England)|December 9, 2023
Population screening requires robust evidence-genomics is no exceptionClare Turnbull, Helen V Firth, Andrew O M Wilkie, et al.
International Journal of Audiology|December 27, 2022
Patient and public involvement in hearing research: opportunities, impact and reflections with case studies from the Manchester Centre for Audiology and DeafnessPiers Dawes, Paolo Arru, Rachel Corry, et al.
The New England Journal of Medicine|May 7, 2010
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery diseaseGregg W Stone, Ali Rizvi, William Newman, et al.
American Heart Journal|November 26, 2013
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trialSorin J Brener, Dean J Kereiakes, Charles A Simonton, et al.
JAMA|April 24, 2008
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trialGregg W Stone, Mark Midei, William Newman, et al.
Molecular Biology Reports|June 23, 2012
Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian populationAl-Motassem Yousef, Nailya R Bulatova, William Newman, et al.
JACC. Cardiovascular Interventions|September 21, 2013
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)George D Dangas, Patrick W Serruys, Dean J Kereiakes, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 17, 2009
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trialAlexandra J Lansky, Vivian G Ng, Halil Mutlu, et al.
Circulation|January 28, 2009
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trialGregg W Stone, Mark Midei, William Newman, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Journal of the American College of Cardiology|April 26, 2011
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trialGregg W Stone, Ali Rizvi, Krishnankutty Sudhir, et al.
Lancet (London, England)|December 9, 2023
Population screening requires robust evidence-genomics is no exceptionClare Turnbull, Helen V Firth, Andrew O M Wilkie, et al.
International Journal of Audiology|December 27, 2022
Patient and public involvement in hearing research: opportunities, impact and reflections with case studies from the Manchester Centre for Audiology and DeafnessPiers Dawes, Paolo Arru, Rachel Corry, et al.
The New England Journal of Medicine|May 7, 2010
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery diseaseGregg W Stone, Ali Rizvi, William Newman, et al.
American Heart Journal|November 26, 2013
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trialSorin J Brener, Dean J Kereiakes, Charles A Simonton, et al.
JAMA|April 24, 2008
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trialGregg W Stone, Mark Midei, William Newman, et al.
Molecular Biology Reports|June 23, 2012
Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian populationAl-Motassem Yousef, Nailya R Bulatova, William Newman, et al.
JACC. Cardiovascular Interventions|September 21, 2013
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)George D Dangas, Patrick W Serruys, Dean J Kereiakes, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|June 17, 2009
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trialAlexandra J Lansky, Vivian G Ng, Halil Mutlu, et al.
Circulation|January 28, 2009
Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trialGregg W Stone, Mark Midei, William Newman, et al.
Pageof 10